PDF
Kurs & Likviditet
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Friday, May 31, 2024: Biosergen AB ("Biosergen" or the "Company") hereby publishes the interim report for the first quarter 2024. The interim report is available as an attached document and on the company website (www.biosergen.net)
Summary of the Interim Report for Q1 2024
2024 2023 2023
TSEK Jan-Mar Jan-Mar Jan-Dec
Profit/loss
Other income 693 5.315 9.378
Profit/loss before depreciation (EBITDA -6.798 -5.029 -27.265
Operating profit/loss before net financials -6.798 -5.029 -27.265
Net financials -95 2 228
Netprofit/loss for the period -6.893 -5.027 -27.037
Earnings per share (SEK) -0,05 -0,18 -0,53
Highlights during Q1 2024- March 26, Biosergen announces the outcome in the rights issue.
- March 15, Members of the board of directors and management subscribe in ongoing rights issue
- March 5, Biosergen publishes prospectus due to rights issue of units.
- March 1, Bulletin from the extraordinary general meeting in Biosergen AB (publ).
- February 12, Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.
- January 30, Biosergen carries out a rights issue of units of approximately SEK 40.5 million, and secures bridge loan.
- January 12, Biosergen Announces Leadership Transition: Peder M. Andersen to Step Down as CEO, Tine Olesen Appointed as Successor.
- April 16, Conversion of paid subscribed units and first day of trading with warrants of series TO3.
- April 9, Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue.
The Financial report can be found on our website: https://biosergen.net/investors/press-releases